openPR Logo

Press Releases from ISA Pharmaceuticals (13 total)

ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …

- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019. The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …

- Recognition for outstanding and innovative cancer research Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute. The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active

ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …

- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC) Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810). This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)

ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present …

Leiden, The Netherlands, January 16, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief will give a talk at the upcoming Keystone Cancer Vaccines Conference in Vancouver, BC, Canada, January 20-24, 2019. The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00

ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …

Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening

ISA Pharmaceuticals Reports Publication of Favorable Phase 2 Results of ISA101 p …

Leiden, The Netherlands, September 27, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced the publication of the results of a Phase 2 combination trial with ISA’s synthetic long-peptide (SLP) HPV-16 vaccine ISA101 and nivolumab, a monoclonal antibody and PD-1 checkpoint inhibitor (NCT02426892). The open-label trial in patients with HPV-16 associated cancers demonstrated safety and efficacy, resulting in an improved survival as compared to historical nivolumab monotherapy results.

ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer

Leiden, The Netherlands, May 23, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immune oncology company, today announced that Gerben Moolhuizen has been promoted from Chief Business Officer to Chief Executive Officer, effective June 1, 2018. He takes over the position from Ronald Loggers, who has served as ISA Pharmaceuticals´ CEO since 2013. "We would like to thank Ronald Loggers for his leadership during the past five years and his contribution in

ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer

- Experienced Chief Medical Officer to advance ISA´s clinical pipeline - Leiden, The Netherlands, April 30, 2018 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Leon Hooftman, MD, to the position of Chief Medical Officer (CMO), effective May 1, 2018. He brings many years of experience in drug development and academic research and has a

ISA Pharmaceuticals' ISA101 Studied in Phase II Oropharyngeal Cancer Combination …

Leiden, The Netherlands, April 26, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX). The goal of the open-label Phase II study in

Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg Un …

- Ceremony Conventio Medicinae held at University Medical Center Leiden, The Netherlands, October 26, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its Chief Scientific Officer, Prof. Cornelis Melief, has received an honorary doctorate from the University Medical Center of Johannes Gutenberg University Mainz, Germany. The honorary doctorate was awarded during a festive ceremony in Mainz on October 25, 2017. Prof. Melief was recognized for his lifetime achievements

Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at …

- Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor Leiden, The Netherlands, September 4, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced the presentation of the results of a clinical Phase II trial initiated by MD Anderson Cancer Center in collaboration with ISA and Bristol-Myers Squibb (NCT02426892) at ESMO 2017 (September 8-12, 2017, Madrid, Spain). In the trial, cancer patients with HPV16+ incurable

Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be …

- Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer Leiden, The Netherlands, May 23, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that an update of the results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer patients (ISA101-CervISA) will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017, Chicago, IL, USA). A poster presentation will be held by Winald

ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Honored by …

-- Cornelis ("Kees") Melief receives lifetime achievement award for his work as a leading immuno-hematologist -- Leiden, The Netherlands, May 11, 2017 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that its Chief Scientific Officer Prof. Cornelis (Kees) Melief has received the first ever lifetime achievement award granted by the Association for Cancer Immunotherapy CIMT for his pioneering research on cancer immunotherapy. The ceremony took place at this year´s